Evidence map›Paper›PMID 41728474›Full record

ArticleCureus2026

Rituximab-Induced Serum Sickness in Patients With Multiple Sclerosis: A Case Report and Literature Review.

Asmae Sikkal, Salma Ouahmane, Hicham El Otmani, Bouchra El Moutawakil, Mohammed Abdoh Rafai

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Asmae SikkalDepartment of Neurology and Clinical Neurophysiological Explorations, Ibn Rochd University Hospital of Casablanca, Casablanca, MAR.
Salma OuahmaneDepartment of Neurology and Clinical Neurophysiological Explorations, Ibn Rochd University Hospital of Casablanca, Casablanca, MAR.
Hicham El OtmaniDepartment of Neurology and Clinical Neurophysiological Explorations, Ibn Rochd University Hospital of Casablanca, Casablanca, MAR.
Bouchra El MoutawakilDepartment of Neurology and Clinical Neurophysiological Explorations, Ibn Rochd University Hospital of Casablanca, Casablanca, MAR.
Mohammed Abdoh RafaiDepartment of Neurology and Clinical Neurophysiological Explorations, Ibn Rochd University Hospital of Casablanca, Casablanca, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rituximab is a chimeric anti-CD20 monoclonal antibody that is becoming increasingly used in multiple sclerosis. In rare cases, rituximab may induce a delayed immune-mediated reaction such as rituximab-induced serum sickness. We report the case of a 49-year-old woman with multiple sclerosis who developed rituximab-induced serum sickness characterized by fever, diffuse rash, lymphadenopathy, and arthralgia nine days after her first rituximab infusion. We reviewed the number of cases in a literature review, discussing their characteristics and mechanisms and the implications for using alternative anti-CD20 monoclonal antibodies such as ocrelizumab or ofatumumab for the management of multiple sclerosis.

Indexed as

immune complex-mediated hypersensitivity reactionmultiple sclerosisrituximabrituximab-induced serum sicknessserum sickness

Identifiers

PMID41728474
PMCPMC12917431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.